These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27518544)

  • 41. A Multinational Comparison of Anti-Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific.
    Parikh R; Pirakitikulr N; Chhablani J; Sakurada Y; Singh RP; Modi YS
    Ophthalmol Retina; 2019 Jan; 3(1):16-26. PubMed ID: 30935655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparing different dosing regimens of bevacizumab in the treatment of neovascular macular degeneration: study protocol for a randomised controlled trial.
    Foss AJ; Childs M; Reeves BC; Empeslidis T; Tesha P; Dhar-Munshi S; Mughal S; Culliford L; Rogers CA; Tan W; Montgomery A
    Trials; 2015 Mar; 16():85. PubMed ID: 25873213
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of Intravitreal Ranibizumab, Aflibercept, and Dexamethasone Implant after Bevacizumab Failure in Macular Edema Secondary to Retinal Vascular Occlusions.
    Hanhart J; Rozenman Y
    Ophthalmologica; 2017; 238(1-2):110-118. PubMed ID: 28535531
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Why using Avastin for eye disease is so difficult.
    Torjesen I
    BMJ; 2012 May; 344():e3012. PubMed ID: 22549057
    [No Abstract]   [Full Text] [Related]  

  • 46. Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health.
    Moreno TA; Kim SJ
    Semin Ophthalmol; 2016; 31(4):378-84. PubMed ID: 27116030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
    Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB
    Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors associated with pain during intravitreal injection of anti-vascular endothelial growth factor.
    Nguyen NCI; Fabro F; Ambresin A; Ezziat S; Bergin C; Mazzocato C; Mantel I
    Eye (Lond); 2018 Sep; 32(9):1544-1546. PubMed ID: 29769650
    [No Abstract]   [Full Text] [Related]  

  • 49. Ziv-aflibercept in macular disease.
    Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
    Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.
    Lehmann-Clarke L; Dirani A; Mantel I; Ambresin A
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):552-5. PubMed ID: 25902119
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [An eye for an eye? Lack of consensus in off-label use of medications leads to major regional differences in medical costs for the treatment of wet AMD in Sweden].
    Bro T
    Lakartidningen; 2017 Nov; 114():. PubMed ID: 29292948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
    Ashraf M; Souka AA; ElKayal H
    Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
    Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
    Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
    Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
    Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early Changes of Retinal Morphology in Therapy of Neovascular Age-Related Macular Degeneration with Three Commonly Used Anti-VEGF Agents.
    Enders P; Sitnilska V; Altay L; Fauser S
    Ophthalmologica; 2018; 239(1):45-51. PubMed ID: 28950272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration.
    Kanadani TCM; Dos Reis Veloso CE; Dorairaj S; Nehemy MB
    Ophthalmic Res; 2017; 58(1):18-26. PubMed ID: 28301850
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period.
    Hutton D; Newman-Casey PA; Tavag M; Zacks D; Stein J
    Health Aff (Millwood); 2014 Jun; 33(6):931-9. PubMed ID: 24889941
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema].
    Kakkassery V; Winterhalter S; Joussen AM
    Klin Monbl Augenheilkd; 2010 Sep; 227(9):701-11. PubMed ID: 20845250
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective.
    Nunes RP; Hirai FE; Rodrigues EB; Farah ME
    Arq Bras Oftalmol; 2020; 83(1):48-54. PubMed ID: 32130306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.